BR-105

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameBR-105
Drug Alias NameBR105BR-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSignal-regulatory protein alpha inhibitors
TargetsSignal-regulatory protein alpha
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHisun Biopharmaceutical Co LtdZhejiang BioRay Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang BioRay Biopharmaceuticals Co LtdHisun Biopharmaceutical Co Ltd
Inactive CompaniesBioRay Pharmaceutical Co Ltd
Active IndicationsLymphoma, Large B-Cell, DiffuseNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A